SCHEMBL30482

SCHEMBL30482

O=C1CCC2(CC1)Cc1ccc(Br)cc1C2=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PARP10 Q53GL7 2/20 0.41
PARP1 P09874 1/20 0.41
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
TDP2 O95551 1/20 0.38
TGM2 P21980 1/20 0.38
CES1 P23141 1/20 0.38
CMA1 P23946 1/20 0.37
AHR P35869 1/20 0.37
S100A4 P26447 1/20 0.36
METAP1 P53582 1/20 0.36
PARP11 Q9NR21 1/20 0.35
KDM1A O60341 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18087904 0.92 TDP1 (0.44) TDP1L3MBTL1PARP10PARP1CA1
SCHEMBL9948162 0.90 TDP1 (0.46) TDP1L3MBTL1PARP10PARP1CA1
SCHEMBL16622013 0.89 TDP1 (0.50) TDP1L3MBTL1PARP10PARP1CA1
SCHEMBL30785 0.88 TDP1 (0.54) TDP1L3MBTL1PARP10PARP1CA1
SCHEMBL9948561 0.87 TDP1 (0.44) TDP1L3MBTL1PARP10PARP1CA1
SCHEMBL1465021 0.85 TDP1 (0.41) TDP1L3MBTL1PARP10PARP1CA1
SCHEMBL30859 0.85 TDP1 (0.41) TDP1L3MBTL1PARP10PARP1CA1
SCHEMBL7889527 0.84 METAP1 (0.41) TDP1L3MBTL1PARP10PARP1CA1
SCHEMBL9948411 0.84 PARP10 (0.40) TDP1L3MBTL1PARP10PARP1CA1
SCHEMBL1465537 0.84 TDP1 (0.41) TDP1L3MBTL1PARP10PARP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3064494-A1 A PROCESS FOR THE PREPARATION OF A CAMSYLATE SALT ((1S)-(+)-10 CAMPHORSULFONIC ACID) OF (1R,1'R,4R)- 4-METHOXY-5\"-METHYL-6'-[5-(PROP-1-YN-1-YL)PYRIDIN- 3-YL]-3'H-DISPIRO[CYCLOHEXANE-1,2'-INDEN-1'2'-IMIDAZOLE]-4\"-AMINE AstraZeneca AB (SE) 2016-09-07 EP claimed
US-10548882-B2 Camsylate salt ASTRAZENECA AB (SE) 2020-02-04 US disclosed
US-10548882-B2 Camsylate salt ASTRAZENECA AB (SE) 2020-02-04 US disclosed
EP-3176172-B1 SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2020-01-29 EP disclosed
EP-3176172-B1 SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2020-01-29 EP disclosed
US-20190262327-A1 COMBINATION OF A BACE INHIBITOR AND AN ANTIBODY OR ANTIGEN-BINDING FRAGMENT FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH THE ACCUMULATION OF AMYLOID BETA ASTRAZENECA AB (SE) 2019-08-29 US disclosed
US-20190262327-A1 COMBINATION OF A BACE INHIBITOR AND AN ANTIBODY OR ANTIGEN-BINDING FRAGMENT FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH THE ACCUMULATION OF AMYLOID BETA ASTRAZENECA AB (SE) 2019-08-29 US disclosed
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
US-10231967-B2 Compounds and their use as BACE inhibitors ASTRAZENECA AB (SE) 2019-03-19 US disclosed
US-20120165347-A1 Compounds and their use as BACE Inhibitors ASTRAZENECA AB (SE) 2012-06-28 US disclosed
US-20120165347-A1 Compounds and their use as BACE Inhibitors ASTRAZENECA AB (SE) 2012-06-28 US disclosed
EP-2406240-A2 INHIBITORS OF BETA-SECRETASE Vitae Pharmaceuticals, Inc. (US) 2012-01-18 EP disclosed
WO-2011106414-A1 INHIBITORS OF BETA-SECRETASE DILLARD LAWRENCE W (US) 2011-09-01 WO disclosed
WO-2011106414-A1 INHIBITORS OF BETA-SECRETASE DILLARD LAWRENCE W (US) 2011-09-01 WO disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 US disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 US disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 US disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 WO disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10548882-B2 Camsylate salt PSEN1, PSEN2, MAPT TDP1 137/4885L3MBTL1 2640/4885PARP10 908/4885
US-10336717-B2 Inhibitors of beta-secretase BACE1, BACE2, PSEN1 TDP1 582/4885L3MBTL1 4257/4885PARP10 896/4885
US-20120165347-A1 Compounds and their use as BACE Inhibitors BACE1, BACE2, APP TDP1 82/4885L3MBTL1 3800/4885PARP10 534/4885
US-10231967-B2 Compounds and their use as BACE inhibitors BACE1, BACE2, APP TDP1 82/4885L3MBTL1 3800/4885PARP10 534/4885
US-20190262327-A1 COMBINATION OF A BACE INHIBITOR AND AN ANTIBODY OR ANTIGEN-BINDING FRAGMENT FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH THE ACCUMULATION OF AMYLOID BETA BACE2, BACE1, APP TDP1 333/4885L3MBTL1 1462/4885PARP10 841/4885
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 TDP1 582/4885L3MBTL1 4257/4885PARP10 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.